Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
Stocks in this Quantisnow insightHealth Care
Historical context for LPCN
Across the 12 sessions after earlier LPCN headlines, the stock closed higher 4 times and lower 7 times, with a median move of 3.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | LPCN | SPY |
|---|---|---|---|
| May 19, 2026 | Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer | -0.5% | -0.7% |
| May 18, 2026 | Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase | -2.2% | -0.1% |
| May 8, 2026 | Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 | -0.8% | +0.8% |
| Apr 6, 2026 | Lipocine downgraded by H.C. Wainwright | -5.4% | +0.5% |
| Mar 10, 2026 | Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 | +2.9% | -0.2% |
| Feb 18, 2026 | Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) | -1.3% | +0.5% |
Keep researching LPCN
Quantisnow market dataNASDAQ
LPCN
Lipocine Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for LPCN
Full LPCN profile on Quantisnow Follow LPCN and get a push notification the moment its next story breaks.